NCT00119613View on ClinicalTrials.gov

A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa

PHASE3CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

January 31, 2007

Study Completion Date

April 30, 2007

Conditions
Small Cell Lung Cancer
Interventions
DRUG

placebo

placebo

DRUG

darbepoetin alfa

darbepoetin alfa

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00119613 - A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa | Biotech Hunter | Biotech Hunter